7 results on '"Garfield, Susan"'
Search Results
2. List of Contributors
- Author
-
Allen, Chris, primary, Anthony, Jack M., additional, Baylor, Norman W., additional, Beeler, John F., additional, Boclair, Dave, additional, Boni, Arthur A., additional, Bradley, Craig C., additional, Busenitz, Lowell W., additional, Byrne, Mark, additional, Calcaterra, Robert J., additional, Conner, John, additional, Elman, Gerry J., additional, Ferguson, Steven M., additional, Ferré, François, additional, Freedman, Toby, additional, Garfield, Susan, additional, Greenwood, The Honorable James C., additional, Gutterson, Neal, additional, Haworth, Philip, additional, Javitt, Gail H., additional, Kaundinya, Uma S., additional, Kirsch, Donald R., additional, Kostov, Konstantin S., additional, Kureczka, Joan E., additional, Langer, Lynn Johnson, additional, Lopez, Maria, additional, Marks, Lara V., additional, Marquet, Magda, additional, Mills, Gayle M., additional, Minshall, Bill, additional, Peterson, Jay, additional, Prusti, Rabi, additional, Sahner, David, additional, Sammut, Stephen M., additional, Shah, Alaap B., additional, Shimasaki, Craig, additional, Spellmeyer, David C., additional, Termeer, Henri A., additional, Tillman, Donna-Bea, additional, Todorova, Gergana, additional, Walker, Tom D., additional, Wanerman, Robert E., additional, Weingart, Laurie R., additional, White, Gladys B., additional, Wuchterl, Don, additional, Zhang, Jay Z., additional, and Zhang, Jimmy Zhimin, additional
- Published
- 2020
- Full Text
- View/download PDF
3. Contributors
- Author
-
Allen, Chris, primary, Anthony, Jack M., additional, Baylor, Norman W., additional, Beeler, John F., additional, Boclair, Dave, additional, Boni, Arthur A., additional, Bradley, Craig C., additional, Burrill, G. Steven, additional, Busenitz, Lowell W., additional, Calcaterra, Robert J., additional, Conner, John, additional, Elman, Gerry J., additional, Ferguson, Steven M., additional, Freedman, Toby, additional, Garfield, Susan, additional, Greenwood, James C., additional, Gutterson, Neal, additional, Haworth, Phil, additional, Kaundinya, Uma S., additional, Kirsch, PhD, Donald R., additional, Kureczka, Joan E., additional, Langer, Lynn Johnson, additional, Lopez, Maria, additional, Marks, Lara V., additional, Minshall, Bill, additional, Peterson, Jay, additional, Prusti, Rabi, additional, Shimasaki, Craig, additional, Termeer, Henri A., additional, Todorova, Gergana, additional, Walker, Tom D., additional, Wanerman, Robert E., additional, Weingart, Laurie R., additional, White, Gladys B., additional, Wuchterl, Don, additional, and Zhang, Jay Z., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Biotechnology Product Coverage, Coding, and Reimbursement Strategies
- Author
-
Wanerman, Robert E., primary and Garfield, Susan, additional
- Published
- 2014
- Full Text
- View/download PDF
5. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
- Author
-
Garfield S, Polisena J, S Spinner D, Postulka A, Y Lu C, Tiwana SK, Faulkner E, Poulios N, Zah V, and Longacre M
- Subjects
- Internationality, Quality Improvement, Pathology, Molecular, Technology Assessment, Biomedical methods, Technology Assessment, Biomedical standards
- Abstract
Background: Health technology assessments (HTAs) are increasingly used to inform coverage, access, and utilization of medical technologies including molecular diagnostics (MDx). Although MDx are used to screen patients and inform disease management and treatment decisions, there is no uniform approach to their evaluation by HTA organizations., Objectives: The International Society for Pharmacoeconomics and Outcomes Research Devices and Diagnostics Special Interest Group reviewed diagnostic-specific HTA programs and identified elements representing common and best practices., Methods: MDx-specific HTA programs in Europe, Australia, and North America were characterized by methodology, evaluation framework, and impact. Published MDx HTAs were reviewed, and five representative case studies of test evaluations were developed: United Kingdom (National Institute for Health and Care Excellence's Diagnostics Assessment Programme, epidermal growth factor receptor tyrosine kinase mutation), United States (Palmetto's Molecular Diagnostic Services Program, OncotypeDx prostate cancer test), Germany (Institute for Quality and Efficiency in Healthcare, human papillomavirus testing), Australia (Medical Services Advisory Committee, anaplastic lymphoma kinase testing for non-small cell lung cancer), and Canada (Canadian Agency for Drugs and Technologies in Health, Rapid Response: Non-invasive Prenatal Testing)., Results: Overall, the few HTA programs that have MDx-specific methods do not provide clear parameters of acceptability related to clinical and analytic performance, clinical utility, and economic impact. The case studies highlight similarities and differences in evaluation approaches across HTAs in the performance metrics used (analytic and clinical validity, clinical utility), evidence requirements, and how value is measured. Not all HTAs are directly linked to reimbursement outcomes., Conclusions: To improve MDx HTAs, organizations should provide greater transparency, better communication and collaboration between industry and HTA stakeholders, clearer links between HTA and funding decisions, explicit recognition of and rationale for differential approaches to laboratory-developed versus regulatory-approved test, and clear evidence requirements., (Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
6. An economic assessment model for in-center, conventional home, and more frequent home hemodialysis.
- Author
-
Komenda P, Gavaghan MB, Garfield SS, Poret AW, and Sood MM
- Subjects
- Australia, Canada, Health Care Costs, Humans, United Kingdom, Hemodialysis, Home economics, Models, Economic
- Abstract
More intensive and/or frequent hemodialysis may provide clinical benefits to patients with end-stage renal disease; however, these dialysis treatments are more convenient to the patients if provided in their homes. Here we created a standardized model, based on a systematic review of available costing literature, to determine the economic viability of providing hemodialysis in the home that arrays costs and common approaches for assessing direct medical and nonmedical costs. Our model was based on data from Australia, Canada, and the United Kingdom. The first year start-up costs for all hemodialysis modalities were higher than in subsequent years with modeled costs for conventional home hemodialysis lower than in-center hemodialysis in subsequent years. Modeled costs for frequent home hemodialysis was higher than both in-center and conventional home hemodialysis in the United Kingdom, but lower than in-center hemodialysis and higher than conventional home hemodialysis in Australia and Canada in subsequent years. The higher costs of frequent compared to conventional home hemodialysis were because of higher consumable usage due to dialysis frequency. Thus, our findings reinforce the conclusions of previous studies showing that home-based conventional and more frequent hemodialysis may provide clinical benefit at reasonable costs.
- Published
- 2012
- Full Text
- View/download PDF
7. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.
- Author
-
Chu YW, Schmitz S, Choudhury B, Telford W, Kapoor V, Garfield S, Howe D, and Gress RE
- Subjects
- Animals, Bone Marrow Cells cytology, Bone Marrow Cells drug effects, Cell Count, Cell Cycle drug effects, Cell Lineage drug effects, Cell Proliferation drug effects, Chemokines metabolism, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells drug effects, Humans, Insulin-Like Growth Factor I administration & dosage, Membrane Glycoproteins metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptor, IGF Type 1 metabolism, Signal Transduction drug effects, T-Lymphocytes cytology, T-Lymphocytes drug effects, Cell Differentiation drug effects, Epithelial Cells cytology, Epithelial Cells drug effects, Insulin-Like Growth Factor I pharmacology, Thymus Gland cytology, Thymus Gland drug effects
- Abstract
Insulin-like growth factor 1 (IGF-1) enhances thymopoiesis but given the broad distribution of IGF-1 receptors (IGF-1Rs), its mechanism of action has remained unclear. To identify points of thymic regulation by IGF-1, we examined its effects on T-cell precursors, thymocytes, and thymic epithelial cells (TECs) in normal and genetically altered mice. In thymus-intact but not thymectomized mice, IGF-1 administration increased peripheral naive and recent thymic emigrant (RTE) populations, demonstrating its effect on T-cell production, not peripheral expansion. IGF-1 administration increased bone marrow LSK (lineage(-), Sca-1(+), c-kit(+)) precursor proliferation and peripheral LSK populations, increased thymocyte populations in a sequential wave of expansion, and proportionately expanded TEC subpopulations and enhanced their chemokine expression. To separate IGF-1's effects on thymocytes and TECs, we generated mice lacking IGF-1R on thymocytes and T cells. Thymocyte and RTE numbers were decreased in these mice, but IGF-1 treatment produced comparable thymocyte numbers to similarly treated wild-type mice. We additionally separated thymic- from LSK-specific effects by demonstrating that IGF-1 increased thymocyte numbers despite impaired early thymic progenitor (ETP) importation in PSGL-1KO mice. These results indicate the critical point thymic function regulation by IGF-1 involves TEC expansion regulating thymocyte precursor entry and facilitating thymocyte development.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.